New and Emerging Treatments for Epilepsy: Review of Clinical Studies of Lacosamide, Eslicarbazepine Acetate, Ezogabine, Rufinamide, Perampanel, and Electrical Stimulation Therapy
Steve S. Chung, Kristen Kelly, Courtney Schusse
J Epilepsy Res. 2011;1(2):35-46.   Published online 2011 Dec 30     DOI: https://doi.org/10.14581/jer.11008
Citations to this article as recorded by Crossref logo
Nucleic Acid Aptamers for Molecular Therapy of Epilepsy and Blood-Brain Barrier Damages
Tatiana N. Zamay, Galina S. Zamay, Natalia A. Shnayder, Diana V. Dmitrenko, Sergey S. Zamay, Victoria Yushchenko, Olga S. Kolovskaya, Vanessa Susevski, Maxim V. Berezovski, Anna S. Kichkailo
Molecular Therapy - Nucleic Acids.2020; 19: 157.     CrossRef
Liquid chromatographic methods for determination of the new antiepileptic drugs stiripentol, retigabine, rufinamide and perampanel: A comprehensive and critical review
Sara Meirinho, Márcio Rodrigues, Ana Fortuna, Amílcar Falcão, Gilberto Alves
Journal of Pharmaceutical Analysis.2020;[Epub]     CrossRef
Dietary therapy is not the best option for refractory nonsurgical epilepsy
María Magdalena Vaccarezza, Walter Horacio Silva
Epilepsia.2015; 56(9): 1330.     CrossRef
Newly available treatments for epilepsy: review of clinical studies of lacosamide, ezogabine, perampanel and eslicarbazepine acetate
Steve S Chung
Clinical Investigation.2014; 4(9): 839.     CrossRef